Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, ...

Linda Yaccarino has a new job in a vastly different industry weeks after her exit as CEO of X, Elon Musk 's social discourse ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

Hims & Hers delivered strong Q2 growth, driven by compounded GLP-1 offerings, but faces uncertainty as regulatory and supply ...

Inspire Medical Systems crashed Tuesday after the maker of implantable sleep apnea devices called out GLP-1 drugs for ...

As consumer interest in metabolic health, gut support and clean-label products accelerates, dietary fiber, like carob, ...

Explore how GLP-1a drugs transform the food industry from a threat to an opportunity. Our 36-page strategy briefing outlines the potential for growth by meeting the rising demand for protein, fiber, ...

MCK's Q1 results are expected to reflect strong prescription volume growth from GLP-1 demand, but lower margins may weigh on profitability.

The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

Though an estimated 17 million U.S. adolescents and young adults were eligible for GLP-1 receptor agonists for conditions ...

GLP-1s are bringing many changes to people's lives. An unexpected and less welcome one? A newfound aversion to meat and other ...

Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival ...